Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Cited by 25 Publications

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )
georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

11 Customer Reviews

FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.
PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.
(A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.
The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.
WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR) at 0.5 μM is included as a control.

Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.
P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	NX\BeXJYU2mwYYPlJGF{e2G7		NVXIZXc1OjRiaB?=		NH\ZOHhKdmirYnn0bY9vKG:oIFPET\|Qh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzKM7:TR?=	NX7IS\|lrOjR4NEGxNFM>
COLO205	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWi3NkBp		MoS1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB\|NjFOwG0>	MWGyOFY1OTFyMx?=
U937	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mln2O\|IhcA>?		MlXWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=>	M1rxVVI1PjRzMUCz
MOLM13	NEe3NoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYXOZ\|cyPzJiaB?=		NWPyN3J5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?	MnrnNlQ3PDFzMEO=
MOLM13	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYjMW5FRPzJiaB?=		MlHCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?	MXGyOFY1OTFyMx?=
MDA-MB-435	NY\IWZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn;4NlQhcA>?		NFzGeoFKSzVyPUCuNVYh\|ryP	NX;JcYFROTV6MEG4N\|E>
K562	MojIR5l1d3SxeHnjJGF{e2G7		MX[5OkBp	MVHEUXNQ	Mnm5TWM2OD1{IN88US=>	NHHzcGQzPDRzN{W2Oi=>
DU145	NWrHeHltS3m2b4TvfIlkKEG\|c3H5		NFixNXo6PiCq	NWXueHBCTE2VTx?=	M2fLVmlEPTB;Nz61JO69VQ>?	M2fnb\|I1PDF5NU[2
MDA-MB-231	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XsbFEh\|ryP	MUKyOEBp	M3XWdWROW09?	NXTobVJCS2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm	NIe1TGgzPDRzN{W2Oi=>
MCF7	NUH6UI9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXqz[VI1OSEQvF2=	NF\mblAzPCCq	MXzEUXNQ	MnzCR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl	M{TzXFI1PDF5NU[2
MCF7	Mn;OT4lv[XOnIFHzd4F6	MWi1JO69VQ>?	MWKyOEBp	MoriSG1UVw>?	M4XUSmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	NFv2ZXYzPDRzN{W2Oi=>
MDA-MB-231	M{jYVGtqdmG\|ZTDBd5NigQ>?	NWPYVnptPSEQvF2=	NIrYXmszPCCq	MXrEUXNQ	M4nKbWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	NInCW4gzPDRzN{W2Oi=>
MDA-MB-231	MWXGeY5kfGmxbjDBd5NigQ>?	M2nFWFEuOTBizszN	M4W0U\|I1KGh?	M4LDXmROW09?	M174coRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	NYLxdIZHOjR2MUe1OlY>
MCF7	M1r5cmZ2dmO2aX;uJGF{e2G7	NXLseohtOS1zMDFOwG0>	MYqyOEBp	M3LoSmROW09?	MYXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?	MonZNlQ1OTd3Nk[=
MDA-MB-231	MmnDSpVv[3Srb36gRZN{[Xl?	NWH2cmNsOC53LUGg{txO	NUexdFNxPDhiaB?=	NHPqe5BFVVOR	NYDaWFRScGG\|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?	NX34dm5VOjR2MUe1OlY>
MCF7	MkjvSpVv[3Srb36gRZN{[Xl?	MUKwMlUuOSEQvF2=	NV;xVHRKPDhiaB?=	NWH3PZNjTE2VTx?=	M4fvVIhieyCwbzDD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm	M4DMPVI1PDF5NU[2
697	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTRTWM2OD1zNEiuN\|ghdk1?	M{\NO3NCVkeHUh?=
P12-ICHIKAWA	NXz2Oow2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTl4LkC0JI5O	M{HjZnNCVkeHUh?=
NB69	M2nQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLOOY1KSzVyPUG2NU45KG6P	MmrrV2FPT0WU
EoL-1	NXjhN5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnlW3RKSzVyPUG4O{4zPiCwTR?=	NWmxWIU5W0GQR1XS
BHT-101	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfNTWM2OD1zOUiuNlUhdk1?	M{DNTHNCVkeHUh?=
SK-NEP-1	NVLYU3ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm1TWM2OD1{MkCuNFIhdk1?	M3Lx[3NCVkeHUh?=
MHH-NB-11	NEnq[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjY[m9OUUN3ME2yNlAvOTlibl2=	MVfTRW5ITVJ?
AsPC-1	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4njemlEPTB;MkWyMlU{KG6P	NXL1PYxZW0GQR1XS
ES1	M1fsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7VXHpFUUN3ME2yOVYvOjVibl2=	MYLTRW5ITVJ?
LAMA-84	M4DNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjxcVBKSzVyPUK1PE4yQSCwTR?=	MorQV2FPT0WU
MOLT-16	M4HLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3ZeoY4UUN3ME2yOVgvPDlibl2=	Mo\EV2FPT0WU
ES7	M2q1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEL3RZhKSzVyPUK3N{4xQSCwTR?=	MoD3V2FPT0WU
KY821	NX\xWY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHaTWM2OD1\|MUSuNUBvVQ>?	M3zSSnNCVkeHUh?=
RT-112	NE\HOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfZSVRVUUN3ME2zNlEvODVibl2=	NYC0OoV{W0GQR1XS
HL-60	NF7YZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTN2MD62OkBvVQ>?	NIXI[nhUSU6JRWK=
MOLT-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmCzTWM2OD1\|NEWuNVMhdk1?	NYO0VoRHW0GQR1XS
KARPAS-45	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoC0TWM2OD1\|N{[uNVYhdk1?	NH7u[IlUSU6JRWK=
SK-N-AS	M1fKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXKTWM2OD1\|OEeuPFMhdk1?	NVTDcFd[W0GQR1XS
CTB-1	NFqxbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n6T2lEPTB;NEC1MlAzKG6P	M{H0[XNCVkeHUh?=
NKM-1	NHTFdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvjTWM2OD12MUGuPFkhdk1?	Mnq4V2FPT0WU
HTC-C3	M1TuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfVZ3ZKSzVyPUSzNk46PSCwTR?=	NHnqT3ZUSU6JRWK=
BE-13	NF21[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13WSGlEPTB;NES0MlI4KG6P	MWDTRW5ITVJ?
KOSC-2	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3qfGpvUUN3ME20OlYvQSCwTR?=	NHXQbFBUSU6JRWK=
NB14	NV32THMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGryVnFKSzVyPUS4N{42QCCwTR?=	MkTnV2FPT0WU
CAL-27	NVvweHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXpc\|RKSzVyPUS5OE42QSCwTR?=	M2rrV3NCVkeHUh?=
H9	M3nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml73TWM2OD12OUWuOFMhdk1?	M1fvTnNCVkeHUh?=
RS4-11	NWXmPYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPmbplKSzVyPUWwOE44OyCwTR?=	MVHTRW5ITVJ?
PA-1	M2HSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:0cmRKSzVyPUWwPU45PiCwTR?=	NXLGOlBzW0GQR1XS
MV-4-11	M{jCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTVzMz64OUBvVQ>?	M4nUZ3NCVkeHUh?=
OS-RC-2	NH[3e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILVVlVKSzVyPUWyNU43OiCwTR?=	NULDWG9OW0GQR1XS
RPMI-8226	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTV{Nj64OkBvVQ>?	NGHzPW5USU6JRWK=
HGC-27	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LEfmlEPTB;NU[0Mlk6KG6P	NHjadm5USU6JRWK=
CHP-212	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTV7Mz61PUBvVQ>?	M3K5UnNCVkeHUh?=
NB10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T6O2lEPTB;NUm5MlE5KG6P	MmPrV2FPT0WU
HH	NHHjZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF34T5lKSzVyPUW5PU41OyCwTR?=	M1fhV3NCVkeHUh?=
EW-16	M4nrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfHTWM2OD14MEOuOVIhdk1?	MYTTRW5ITVJ?
ES8	NIDKWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTZyNT6yNUBvVQ>?	MnXZV2FPT0WU
HAL-01	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDadGVQUUN3ME22NFUvPjdibl2=	NUPsTWxyW0GQR1XS
A204	NVTrc5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\ZPGlEPTB;NkOzMlkyKG6P	M4HmNHNCVkeHUh?=
MHH-PREB-1	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTkdpdZUUN3ME22N\|YvQTlibl2=	NEm0NlFUSU6JRWK=
EM-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTZ3MD62OEBvVQ>?	NELjdpFUSU6JRWK=
BV-173	NWHoSYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLYS29KSzVyPU[1Nk41QCCwTR?=	NFPJPIVUSU6JRWK=
ONS-76	M4Xv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTZ5Nz64NkBvVQ>?	M3WydXNCVkeHUh?=
KM-H2	NYDqR24yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILNOIJKSzVyPU[5OU42PCCwTR?=	NET3epRUSU6JRWK=
D-263MG	NXHjT5FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTdzNz6xNkBvVQ>?	NYLPTpBIW0GQR1XS
ES3	NIn0NJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTd{OD65N{BvVQ>?	MVjTRW5ITVJ?
VA-ES-BJ	NFLQ[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXqzU4ZXUUN3ME23N\|IvOjdibl2=	NVPVOJpVW0GQR1XS
NBsusSR	NYDpR5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTMTWM2OD15NEKuPVkhdk1?	MYTTRW5ITVJ?
NCI-H520	NXjmc4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvUU4JKSzVyPUe0Ok42OiCwTR?=	MVzTRW5ITVJ?
ES5	NEnBSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\uN4tKSzVyPUe1Nk45KG6P	NXnvT3c2W0GQR1XS
T-24	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzw[4ExUUN3ME23O\|gvPzFibl2=	NHXpeJVUSU6JRWK=
SW962	NU\XUos6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPxfGNEUUN3ME24NFgvPjNibl2=	M{LrVHNCVkeHUh?=
EW-3	NULNRnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXRUHdvUUN3ME24NFgvPzZibl2=	NVrsc3NyW0GQR1XS
RXF393	NILpfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ruN2lEPTB;OEGyMlc6KG6P	M3vkNHNCVkeHUh?=
U251	NUHzO3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLKRoZKUUN3ME24NVMvQDhibl2=	M4\Sd3NCVkeHUh?=
CAMA-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HWNGlEPTB;OEOzMlk1KG6P	MleyV2FPT0WU
JVM-3	NFHMO\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTh3MT63PEBvVQ>?	M4[5VXNCVkeHUh?=
COLO-800	NGS3dmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTh7Nz63PEBvVQ>?	NEO5ZXVUSU6JRWK=
OVCAR-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rY[GlEPTB;OUCwMlEhdk1?	M4HVNHNCVkeHUh?=
LB1047-RCC	NEfz[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7pNFRvUUN3ME25NlcvPTZibl2=	NWnBO3JFW0GQR1XS
SW954	NWnrTmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlu5TWM2OD17MkmuOFEhdk1?	M3ruOXNCVkeHUh?=
J-RT3-T3-5	NVTzb5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13qRWlEPTB;OUO2MlA3KG6P	MmfkV2FPT0WU
Mewo	NXTGd2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWr4VHZqUUN3ME25N\|YvPiCwTR?=	NVzLbHJSW0GQR1XS
NCI-H1770	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW5TWM2OD17NECuOVUhdk1?	M1TNWnNCVkeHUh?=
HO-1-N-1	NHK5dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fyTmlEPTB;OU[yMlgyKG6P	M2T1dHNCVkeHUh?=
HSC-3	NXXtPXVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\B[mlEPTB;OU[2MlQ5KG6P	MYnTRW5ITVJ?
TYK-nu	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTl7OD6yOUBvVQ>?	NHzQWXRUSU6JRWK=
KYSE-150	M4DrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LRW2lEPTB;MT6wNFA4PiEQvF2=	NXvVUlZUW0GQR1XS
SN12C	NInaXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\jTWM2OD1zLkCwPFc2KM7:TR?=	NUG4OVBFW0GQR1XS
MOLT-13	NEjwUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PWT2lEPTB;MT6wNVQzOSEQvF2=	MUHTRW5ITVJ?
TE-11	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjCTWM2OD1zLkC0PFEzKM7:TR?=	MVfTRW5ITVJ?
DB	NYmzcoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzBTWM2OD1zLkC3Nlc{KM7:TR?=	NHvDTnBUSU6JRWK=
CAL-39	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXlZ21lUUN3ME2xMlA4PTJ{IN88US=>	MU\TRW5ITVJ?
A3-KAW	M2r1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPjTWM2OD1zLkC4OFA5KM7:TR?=	MYPTRW5ITVJ?
CHP-134	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTRTWM2OD1zLkGxPFA4KM7:TR?=	NX7ESG94W0GQR1XS
TGW	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFwMUKzPVUh\|ryP	NInJT3ZUSU6JRWK=
QIMR-WIL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluwTWM2OD1zLkGzNVM1KM7:TR?=	NXTCWoNJW0GQR1XS
NCI-SNU-1	NETzWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjTVo5OUUN3ME2xMlE3OzV2IN88US=>	NH\BTZJUSU6JRWK=
CGTH-W-1	NYPEb3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfhWpFkUUN3ME2xMlE4OTh4IN88US=>	NFf2VmRUSU6JRWK=
MHH-ES-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTFwMUe5PFYh\|ryP	MX7TRW5ITVJ?
LB2241-RCC	M2Ps[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILwWHNKSzVyPUGuNVg3OiEQvF2=	MXHTRW5ITVJ?
ML-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;G[GlEPTB;MT6yNFc{PCEQvF2=	NITMe4FUSU6JRWK=
COR-L23	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3juOmlEPTB;MT6yNlk{OyEQvF2=	M1rSOnNCVkeHUh?=
BFTC-905	NYrOT5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFSySpZKSzVyPUGuNlQzPjdizszN	NWDveIY1W0GQR1XS
Hs-578-T	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlO4TWM2OD1zLkK1PFE4KM7:TR?=	MX3TRW5ITVJ?
KG-1	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rGSWlEPTB;MT6yOlY5PiEQvF2=	Mnj2V2FPT0WU
HEL	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT4TWM2OD1zLkK5N\|M5KM7:TR?=	MmLsV2FPT0WU
A549	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXTTWM2OD1zLkK5N\|k6KM7:TR?=	NEO3SIdUSU6JRWK=
COLO-741	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTFwM{KwPFkh\|ryP	MojtV2FPT0WU
PC-3	M4\JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HrbWlEPTB;MT6zOVIzOSEQvF2=	MnvTV2FPT0WU
HOS	M4PYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDLVHdKSzVyPUGuN\|UzQTZizszN	NV7reYt1W0GQR1XS
HT-1080	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkGxTWM2OD1zLkO3OVE6KM7:TR?=	M3;0UHNCVkeHUh?=
TE-8	NUXBZ5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX74bG9oUUN3ME2xMlQyPzd2IN88US=>	MUnTRW5ITVJ?
BHY	NES1fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK4epJKSzVyPUGuOFY6OjNizszN	MnLvV2FPT0WU
BB65-RCC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e1XGlEPTB;MT61NFUzQCEQvF2=	NITMU\|hUSU6JRWK=
HN	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwNUSwO\|Eh\|ryP	MWfTRW5ITVJ?
NCI-H441	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwNUS5NFch\|ryP	NFnYW\|VUSU6JRWK=
RPMI-8866	NIjIUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;LTWM2OD1zLkW4OVA4KM7:TR?=	MU\TRW5ITVJ?
CAL-62	NYDMeGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXOzVWQ3UUN3ME2xMlYxQDZ{IN88US=>	MkLjV2FPT0WU
MG-63	NWrROo96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwNkG4NVMh\|ryP	NEC2OGRUSU6JRWK=
SK-LU-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1j1R2lEPTB;MT62NlE2OiEQvF2=	M{HocnNCVkeHUh?=
BCPAP	NIDCZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfyTlQzUUN3ME2xMlY3PDV5IN88US=>	MlHXV2FPT0WU
22RV1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXhUmVpUUN3ME2xMlY4QDR\|IN88US=>	NYDCTWQ5W0GQR1XS
T47D	MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3JTWM2OD1zLk[4NFYyKM7:TR?=	M2XmW3NCVkeHUh?=
MSTO-211H	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjzVVlKSzVyPUGuOlk3ODNizszN	M4r4ZXNCVkeHUh?=
DEL	NFHnXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFwN{CyO\|Mh\|ryP	MX;TRW5ITVJ?
H4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fPWWlEPTB;MT63N\|IyOiEQvF2=	MkS5V2FPT0WU
CAL-51	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D2cWlEPTB;MT63OFg2PSEQvF2=	MUTTRW5ITVJ?
ABC-1	NFvvSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHpXmxmUUN3ME2xMlc5PTh{IN88US=>	M{\LbHNCVkeHUh?=
MZ2-MEL	NHrBOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1viVmlEPTB;MT63PVU1OiEQvF2=	MYPTRW5ITVJ?
YKG-1	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLFTWM2OD1zLkixNFYyKM7:TR?=	NE\RN4JUSU6JRWK=
KM12	NFT5PVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT1PINRUUN3ME2xMlgyPjB{IN88US=>	MV7TRW5ITVJ?
L-363	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXQfVlKSzVyPUGuPFc1OTJizszN	NHy1RoFUSU6JRWK=
KU812	M2DOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFwOEmyPFIh\|ryP	Ml\pV2FPT0WU
LOXIMVI	M3O2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlK5TWM2OD1zLkmxNlI5KM7:TR?=	M1njdHNCVkeHUh?=
G-401	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLmW2FNUUN3ME2xMlkzPDJ6IN88US=>	MW\TRW5ITVJ?
SW780	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlftTWM2OD1zLkm2NlQ3KM7:TR?=	MonOV2FPT0WU
SW872	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[2fVNKSzVyPUGuPVg{OyEQvF2=	NEjQSGRUSU6JRWK=
NB7	NF[3R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjLTWM2OD1zLkm5N\|I{KM7:TR?=	MoHSV2FPT0WU
T98G	NIP4bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX2foNKSzVyPUKuNFA3PjZizszN	MW\TRW5ITVJ?
SW1710	NEPvWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[4TWM2OD1{LkC2PVQ2KM7:TR?=	NF;tboVUSU6JRWK=
NCI-H1573	NXXtclZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrrTWM2OD1{LkC3Nlk5KM7:TR?=	MlvuV2FPT0WU
KE-37	NHjLcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlroTWM2OD1{LkC4PVUyKM7:TR?=	NWK5OnpjW0GQR1XS
786-0	MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXidVFvUUN3ME2yMlE2PDN7IN88US=>	NHfiRWVUSU6JRWK=
SAS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLOTWM2OD1{LkKwN\|c1KM7:TR?=	Mny0V2FPT0WU
CAL-54	NEXMXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJwMkC0NVMh\|ryP	NFG3fXBUSU6JRWK=
SF268	M4jhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTFTWM2OD1{LkKzNVIzKM7:TR?=	NXvhXo0yW0GQR1XS
SW620	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M160Z2lEPTB;Mj6yOlE3QSEQvF2=	M2rPWXNCVkeHUh?=
MN-60	NHTsdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlW5TWM2OD1{LkOxNFYh\|ryP	NGnRVoRUSU6JRWK=
EFO-27	M3XId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJwM{KwOVgh\|ryP	Ml3mV2FPT0WU
NCI-H747	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGK4PZFKSzVyPUKuN\|IyQTlizszN	NUm0O\|BHW0GQR1XS
HCC2218	NVHteol1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJwM{WzO\|Qh\|ryP	NV7NSWxnW0GQR1XS
MIA-PaCa-2	NX;C[llST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPvO2loUUN3ME2yMlM3PDN5IN88US=>	NVrnOG5WW0GQR1XS
SJSA-1	M2HxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUP0W2Z{UUN3ME2yMlM4Pzl4IN88US=>	Mmf0V2FPT0WU
RKO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDDO\|BDUUN3ME2yMlM5PDl4IN88US=>	M4HM[XNCVkeHUh?=
NB6	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTJwNECzO\|Qh\|ryP	MV3TRW5ITVJ?
ES4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7ufFZKSzVyPUKuOFU1OjJizszN	MoTyV2FPT0WU
EGI-1	NXKwe5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJwNE[4PFMh\|ryP	NGXscVJUSU6JRWK=
CTV-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmO1TWM2OD1{LkWyO\|c{KM7:TR?=	MnfHV2FPT0WU
NCI-H1355	M3PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzwTWM2OD1{LkW1PVUyKM7:TR?=	NH7Xc2ZUSU6JRWK=
GT3TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHp[VhKSzVyPUKuOVkyQTlizszN	NWO2SlFvW0GQR1XS
SK-HEP-1	M3LZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF30OW1KSzVyPUKuOVkzPjZizszN	M4TI[3NCVkeHUh?=
GAMG	M3fYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrmO2FwUUN3ME2yMlU6Ozl2IN88US=>	NUDVXZNiW0GQR1XS
SK-MES-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HFWmlEPTB;Mj62NVgxOyEQvF2=	NH\qW2hUSU6JRWK=
RO82-W-1	NGG2UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJwNkKwOVch\|ryP	NFTWZ5NUSU6JRWK=
ECC10	NV;mXFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TkeWlEPTB;Mj63NFIxPiEQvF2=	M{HZOXNCVkeHUh?=
MCF7	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjH[XZKSzVyPUKuO\|E1PjRizszN	NYG2dG92W0GQR1XS
D-283MED	NXq4ZoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXKZYRKSzVyPUKuO\|I1OyEQvF2=	MkXLV2FPT0WU
RPMI-7951	NHO3fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGH2bWtKSzVyPUKuO\|U3QTRizszN	MlnyV2FPT0WU
Ramos-2G6-4C10	M{jH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnixTWM2OD1{Lke3NFk6KM7:TR?=	M1XBfnNCVkeHUh?=
KGN	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\EbGlEPTB;Mj64NVg5PCEQvF2=	NGDYVGlUSU6JRWK=
NUGC-3	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXqzSIN4UUN3ME2yMlgzPTB3IN88US=>	MkLRV2FPT0WU
NCI-H292	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny3TWM2OD1{Lki1NFU{KM7:TR?=	Ml;LV2FPT0WU
Becker	NFjaUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJwOUW4N\|Ih\|ryP	M4nMfnNCVkeHUh?=
NCI-H1299	M{XBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[wfpNWUUN3ME2zMlA2OjZ\|IN88US=>	M4joSHNCVkeHUh?=
ETK-1	NIXLXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlj5TWM2OD1\|LkC1OFMh\|ryP	NYXBZ\|M1W0GQR1XS
TK10	NWPnWZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTNwMkCxOlUh\|ryP	MV;TRW5ITVJ?
VMRC-RCZ	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DOR2lEPTB;Mz6zOlQ5QCEQvF2=	Mn\qV2FPT0WU
YH-13	NWD4OFlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTNwNESwO\|kh\|ryP	NIrwd4pUSU6JRWK=
DU-145	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\WVJhFUUN3ME2zMlQ3OjZ7IN88US=>	MmX4V2FPT0WU
SW1088	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjYNlRKSzVyPUOuOFc1PyEQvF2=	Ml;kV2FPT0WU
HOP-92	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWK4fm5RUUN3ME2zMlUxOzR{IN88US=>	NIT4TFhUSU6JRWK=
KP-N-YS	M2\5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjaOoVXUUN3ME2zMlYzOTN7IN88US=>	NFzxW5RUSU6JRWK=
NCI-H460	NGfoVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNwNk[3N{DPxE1?	NHLINnlUSU6JRWK=
U-2-OS	NHWzSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHZRWxKSzVyPUOuO\|I2OzVizszN	M4PmfnNCVkeHUh?=
A101D	NHq4SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[xVnNtUUN3ME2zMlc3QTN4IN88US=>	Mm\yV2FPT0WU
MDA-MB-231	M1\PbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LmVWlEPTB;Mz64NVk2OSEQvF2=	MVTTRW5ITVJ?
IST-MES1	NIH1em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTweVNKSzVyPUOuPFMzKM7:TR?=	NYLP[WU5W0GQR1XS
COR-L105	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jBSGlEPTB;ND6wNVgh\|ryP	NHfJU4pUSU6JRWK=
NCI-H1437	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjFPWNKSzVyPUSuNFI{ODJizszN	NH\SUYdUSU6JRWK=
CAL-85-1	NGOyZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknsTWM2OD12LkCyOFYyKM7:TR?=	MUnTRW5ITVJ?
MZ1-PC	M{PEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzWTWM2OD12LkG4OVU3KM7:TR?=	MoTzV2FPT0WU
VM-CUB-1	NGjJb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3HTWM2OD12LkOxNlg1KM7:TR?=	MlT4V2FPT0WU
CHL-1	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLGTWM2OD12LkOyNVY6KM7:TR?=	NYjpc4VkW0GQR1XS
MDA-MB-361	NGnmR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTRwM{OxOVMh\|ryP	MXHTRW5ITVJ?
NCI-H661	NEXrdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnNVpBrUUN3ME20MlUxODl{IN88US=>	NFi3eVRUSU6JRWK=
EW-11	NWnlT3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f6R2lEPTB;ND61NlI{OSEQvF2=	NVGyRZM2W0GQR1XS
BEN	NFPjeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrFTWM2OD12LkWyPFE2KM7:TR?=	MlrVV2FPT0WU
BFTC-909	M3;oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojTTWM2OD12LkW2Nlc2KM7:TR?=	M{L0OHNCVkeHUh?=
NCI-H2087	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\lTWM2OD12LkW4NVY1KM7:TR?=	NHTkZVlUSU6JRWK=
RVH-421	NW\FWJZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTRwNk[2PUDPxE1?	NGTKe5RUSU6JRWK=
P30-OHK	M4\2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTRwNkiwNFgh\|ryP	MorRV2FPT0WU
NCI-H28	NYT0W2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTxOnZHUUN3ME20MlgyPjZzIN88US=>	MYrTRW5ITVJ?
ES6	NETLU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojrTWM2OD12LkizNFE3KM7:TR?=	NWXQNmg5W0GQR1XS
769-P	NED2c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fqN2lEPTB;ND64OVkzPiEQvF2=	MULTRW5ITVJ?
OE33	M2HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3xZZF2UUN3ME20Mlg5OTZzIN88US=>	NYTsWnA1W0GQR1XS
SW982	M4HIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTRwOUWwOlEh\|ryP	NFXwZ3pUSU6JRWK=
A388	M3rzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HMcWlEPTB;NT6wNlk5OyEQvF2=	NFXFWIdUSU6JRWK=
TI-73	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TKe2lEPTB;NT6wOlE6PCEQvF2=	MW\TRW5ITVJ?
HCT-116	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLUU3BKSzVyPUWuNFk5QDlizszN	MYDTRW5ITVJ?
HuP-T3	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTVwMUi3NFkh\|ryP	NWPl[Hk1W0GQR1XS
G-402	NHLrcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPI[W5wUUN3ME21MlE6PDF4IN88US=>	MYHTRW5ITVJ?
NCI-H1792	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\Ye2lEPTB;NT6yOFYzOiEQvF2=	NFrFO5RUSU6JRWK=
NCI-H209	NGXZd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XDSmlEPTB;NT6yOVk1OiEQvF2=	MkfqV2FPT0WU
NCI-H1650	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTSTWM2OD13LkOwOlM1KM7:TR?=	NEC0bmJUSU6JRWK=
LCLC-97TM1	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTzepVKSzVyPUWuN\|E5ODhizszN	MoXWV2FPT0WU
S-117	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTVwM{[5O\|Yh\|ryP	MkTJV2FPT0WU
GI-ME-N	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrabnBKSzVyPUWuN\|k3QDFizszN	MoHGV2FPT0WU
NCI-H2122	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTVwNEmzPVch\|ryP	MnvlV2FPT0WU
NCI-H1793	NU\lOWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rCNGlEPTB;NT62O\|U6OyEQvF2=	NIXaR2pUSU6JRWK=
C2BBe1	NVjoPHdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojETWM2OD13LkewNFg5KM7:TR?=	NXn0bpI1W0GQR1XS
TE-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jYUmlEPTB;NT64NFU2PiEQvF2=	MnTlV2FPT0WU
LCLC-103H	NHnMRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPnV\|IxUUN3ME21MlkyPyEQvF2=	M4fx[3NCVkeHUh?=
A673	M3S2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\uTWM2OD13LkmxPVMzKM7:TR?=	M3fzUnNCVkeHUh?=
BB30-HNC	NWTIO4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTVwOUizOkDPxE1?	NEP2cZBUSU6JRWK=
SF295	NIW0R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlK1TWM2OD14LkCwOFIzKM7:TR?=	MX;TRW5ITVJ?
KU-19-19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTlNoJKSzVyPU[uNFE4OzFizszN	MXLTRW5ITVJ?
CFPAC-1	NUXaNJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTyTWM2OD14LkC0OFQ{KM7:TR?=	M3rnN3NCVkeHUh?=
LoVo	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjGdY1KSzVyPU[uNFUxPjNizszN	MkXoV2FPT0WU
8505C	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfNepBKSzVyPU[uNFc2PzNizszN	NX\WZ3NTW0GQR1XS
GMS-10	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHqfpE6UUN3ME22MlE2ODB{IN88US=>	MlrVV2FPT0WU
Ca9-22	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvFZYZKSzVyPU[uNVY4OSEQvF2=	M{jZRXNCVkeHUh?=
DOK	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTZwMkKwO\|Ih\|ryP	NYDjVI1PW0GQR1XS
FADU	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvCRoN4UUN3ME22MlI3ODN7IN88US=>	NHHJO2FUSU6JRWK=
BxPC-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\NOWlEPTB;Nj6yO\|MzKM7:TR?=	MlO1V2FPT0WU
CAL-33	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlH0TWM2OD14LkK5NlAyKM7:TR?=	MWrTRW5ITVJ?
SHP-77	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorDTWM2OD14LkOxOVEzKM7:TR?=	Ml72V2FPT0WU
LXF-289	NVeyd3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXw[213UUN3ME22MlM{PDV3IN88US=>	NVL3eolIW0GQR1XS
GB-1	M{DENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTZwM{iyJO69VQ>?	NV3rTW1HW0GQR1XS
KS-1	NUXQeWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHTTWM2OD14LkO4OFQ4KM7:TR?=	M1OydnNCVkeHUh?=
D-502MG	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHYTWM2OD14LkSyN\|c3KM7:TR?=	Mlm0V2FPT0WU
LAN-6	NFLDS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS4OGxKSzVyPU[uOVExOjNizszN	Mn\sV2FPT0WU
H-EMC-SS	NID2OmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrZ[JFKSzVyPU[uOVYyPDdizszN	Mn[4V2FPT0WU
LC-2-ad	M1Xm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTZwNkCwO\|Yh\|ryP	MXnTRW5ITVJ?
NCI-H1693	NX7zXVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1S1dmlEPTB;Nj62NlIyPSEQvF2=	M{\YOXNCVkeHUh?=
SK-N-FI	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLKdIFKSzVyPU[uO\|UxPDRizszN	M1jY[XNCVkeHUh?=
D-423MG	NXflWZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1W4VGlEPTB;Nj63OlEyPyEQvF2=	MXjTRW5ITVJ?
KNS-42	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO3eWZ[UUN3ME22Mlc5OTl5IN88US=>	MoPWV2FPT0WU
GCT	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH0TWM2OD14LkmzPEDPxE1?	M1TCWHNCVkeHUh?=
DSH1	M4\EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTTTWM2OD15LkC2N\|Mh\|ryP	M2HQRnNCVkeHUh?=
D-247MG	M4ixWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHzOGF3UUN3ME23MlA4QDhzIN88US=>	MY\TRW5ITVJ?
NCI-SNU-5	NWXFc4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLsfIZKSzVyPUeuNVg{PzFizszN	NFnhTWxUSU6JRWK=
TE-6	NELzUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXZUIY6UUN3ME23MlIxPjBzIN88US=>	MU\TRW5ITVJ?
NOMO-1	NGnicI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1e4RmlEPTB;Nz6yNlEzPyEQvF2=	NFfQfnJUSU6JRWK=
NB17	NV;MRoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTdwM{CzNFkh\|ryP	MnHpV2FPT0WU
EW-22	NXviSJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2D2OWlEPTB;Nz6zOFM1QCEQvF2=	M4TvVnNCVkeHUh?=
EW-13	M{nIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HOdGlEPTB;Nz6zOVE3OiEQvF2=	M1q1bHNCVkeHUh?=
DOHH-2	NGXHW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTdwNESwNkDPxE1?	NX3tVHI6W0GQR1XS
TGBC1TKB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTdwNEm4PVkh\|ryP	M{DnVnNCVkeHUh?=
GR-ST	NUjiemxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT0UpJKSzVyPUeuOVI2QTRizszN	NFzueXVUSU6JRWK=
KYSE-520	NYDUWnplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTae\|hKUUN3ME23MlU2PTF3IN88US=>	NFrZU\|hUSU6JRWK=
CAPAN-1	M3;BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUmxW4NWUUN3ME23MlU6PTFizszN	Mn;nV2FPT0WU
HCE-4	NI\ueZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjNfoVKSzVyPUeuOlIzPzlizszN	NYT6fZREW0GQR1XS
MLMA	M1nz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVroSXg2UUN3ME23MlYzQTV5IN88US=>	M{fF[nNCVkeHUh?=
HT-144	NIHWTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vYXmlEPTB;Nz62OVM3QCEQvF2=	MY\TRW5ITVJ?
KYSE-180	NX7Bd3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrwTWM2OD15LkexNVY6KM7:TR?=	M2[3UXNCVkeHUh?=
TE-5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HIeWlEPTB;Nz65OVk4OSEQvF2=	M{fLOnNCVkeHUh?=
IGROV-1	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTdwOUi1OVEh\|ryP	MX;TRW5ITVJ?
NCI-H1581	NI\uO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRThwMEGyJO69VQ>?	NWTTellIW0GQR1XS
SW1990	M4PQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW0ZmdKSzVyPUiuNFQ3PTlizszN	Mnv1V2FPT0WU
EFM-19	M1Tjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHHRXBsUUN3ME24MlA5PTR3IN88US=>	NVPKXHVQW0GQR1XS
OGR-1	NVqzOGcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HhWWlEPTB;OD60N\|AzOyEQvF2=	NG\peINUSU6JRWK=
U-118-MG	NVXuUGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDabndKSzVyPUiuOFM1PjNizszN	M1nFfnNCVkeHUh?=
SK-OV-3	M4rV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHwOJhKSzVyPUiuOFY4PjVizszN	MoO2V2FPT0WU
KNS-62	NGe1N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvrWlNKSzVyPUiuOVE4PjFizszN	M3zNTHNCVkeHUh?=
GOTO	NVnOVVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M16zRWlEPTB;OD61O\|Y{PSEQvF2=	NEPtd\|ZUSU6JRWK=
8305C	M370XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH[yTIhKSzVyPUiuO\|A1QDRizszN	MYXTRW5ITVJ?
RPMI-2650	NHLlcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRThwN{G5OVUh\|ryP	NXHiOIdHW0GQR1XS
NEC8	M{fNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRThwN{SzNFch\|ryP	NG\yZ5FUSU6JRWK=
KYSE-450	NYm5UlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRThwOE[1OFgh\|ryP	MknLV2FPT0WU
RMG-I	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r4TmlEPTB;OT6xOFA2QCEQvF2=	MofHV2FPT0WU
CAKI-1	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\SOWlEPTB;OT6zNVk4QSEQvF2=	NEL3cnFUSU6JRWK=
KYSE-510	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnDWVNKSzVyPUmuN\|U4PzhizszN	MkTVV2FPT0WU
A4-Fuk	NYLjTZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Li[mlEPTB;OT6zOlcxOSEQvF2=	NIPzWmJUSU6JRWK=
AN3-CA	NWXW[mo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz1U25KSzVyPUmuOFU1PDRizszN	MVHTRW5ITVJ?
SK-N-DZ	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTlwN{K4OFkh\|ryP	MYXTRW5ITVJ?
HSC-2	NFiyUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTlwN{[2Nlkh\|ryP	Ml32V2FPT0WU
EW-1	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonGTWM2OD17Lke5N\|Y6KM7:TR?=	M4PCc3NCVkeHUh?=
D-566MG	M4r4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjJUopKSzVyPUmuPFM3PjRizszN	M1:yTnNCVkeHUh?=
COLO-792	M{HveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHVVGhLUUN3ME25Mlk5PzR4IN88US=>	M2fpWHNCVkeHUh?=
TE-10	NV3he3BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULnOZVrUUN3ME2xNE4xOzl4IN88US=>	MWfTRW5ITVJ?
NCI-H650	M{\ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTFyLkSyPFYh\|ryP	MVzTRW5ITVJ?
U-266	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPK[JUxUUN3ME2xNE41PTVizszN	MkWyV2FPT0WU
Detroit562	M4rNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXRNmJWUUN3ME2xNU4xPTF3IN88US=>	M1[3OnNCVkeHUh?=
NH-12	NXS0OJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFzLkG0OFYh\|ryP	NUPXenhPW0GQR1XS
CO-314	NWPSOnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmmzTWM2OD1zMT6yPFQzKM7:TR?=	MkTtV2FPT0WU
IST-MEL1	NYnyO5hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFzLkWzNlMh\|ryP	M2HtTXNCVkeHUh?=
KNS-81-FD	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWKwc2dRUUN3ME2xNU42PTJ5IN88US=>	NYHUSpgzW0GQR1XS
SW1463	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfVOFBKSzVyPUGxMlU6QDlizszN	MWrTRW5ITVJ?
NCI-H23	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn1TWM2OD1zMT62OVUzKM7:TR?=	NV3nUHk1W0GQR1XS
SK-MEL-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPDUGhHUUN3ME2xNU44OTl5IN88US=>	NXTkeod4W0GQR1XS
NB13	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnNTWM2OD1zMj6xOFk2KM7:TR?=	NEC0T5pUSU6JRWK=
Daoy	NHvqToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33HRmlEPTB;MUKuNlg2PiEQvF2=	MWPTRW5ITVJ?
NCI-H1623	M3zYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnqzTWM2OD1zMj6zPFAyKM7:TR?=	M{HGUHNCVkeHUh?=
NMC-G1	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljXTWM2OD1zMj63NVch\|ryP	NYjkSpZGW0GQR1XS
DK-MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXtVXhKSzVyPUGyMlk1QDJizszN	NXm0NmZTW0GQR1XS
TCCSUP	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX2PFZKSzVyPUGzMlEzQDRizszN	NF:xfodUSU6JRWK=
SCC-15	M33JTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrBcXFKSzVyPUGzMlI3PTFizszN	MorGV2FPT0WU
NOS-1	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDQTWM2OD1zMz6yPFk{KM7:TR?=	MXXTRW5ITVJ?
RH-1	NFn2b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XQeGlEPTB;MUOuN\|A{PyEQvF2=	NFnSWJdUSU6JRWK=
SK-MEL-3	NVzBdnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF\|LkO3Nlgh\|ryP	NGDXbZdUSU6JRWK=
NB5	Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTF\|LkSwOlch\|ryP	M3POTXNCVkeHUh?=
SNU-387	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVmzXml3UUN3ME2xN{42ODd{IN88US=>	MVrTRW5ITVJ?
CAL-120	NUSwSWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2e5d2lEPTB;MUOuOlcyQCEQvF2=	MWfTRW5ITVJ?
Mo-T	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF\|LkewO{DPxE1?	Mk\aV2FPT0WU
LNCaP-Clone-FGC	M3PUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW1TWM2OD1zMz63PVkzKM7:TR?=	MYnTRW5ITVJ?
CAN	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2SyR2lEPTB;MUSuNFI5QCEQvF2=	NInSZnBUSU6JRWK=
SK-MEL-30	M4XFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ewN2lEPTB;MUSuNFY{KM7:TR?=	M3X5SnNCVkeHUh?=
COLO-678	NHPjTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDRcmZnUUN3ME2xOE4xQDJ{IN88US=>	MoLiV2FPT0WU
SCC-9	NYfKd4pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3MU2ZtUUN3ME2xOE4yODJzIN88US=>	NHzFS2hUSU6JRWK=
KINGS-1	NWHYdGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\zTWM2OD1zND6xOFAzKM7:TR?=	MofzV2FPT0WU
SL-513	NIHVe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnQcZpKSzVyPUG0MlE5PyEQvF2=	NIW4bppUSU6JRWK=
HLE	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HmW2lEPTB;MUSuN\|g2OiEQvF2=	MUXTRW5ITVJ?
SW1573	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\xPZZKSzVyPUG0MlQ1OzVizszN	NXzMTGtqW0GQR1XS
KYSE-140	NGHHbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrWTWM2OD1zND62N\|I4KM7:TR?=	M3rzb3NCVkeHUh?=
SK-PN-DW	M3K2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P4[WlEPTB;MUSuPFAxOSEQvF2=	Mo\NV2FPT0WU
A253	NELSU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PzdWlEPTB;MUWuNFYzPSEQvF2=	M2DBUXNCVkeHUh?=
CAL-12T	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF3LkS2OlIh\|ryP	NHLmfmlUSU6JRWK=
COLO-679	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TucWlEPTB;MUWuO\|Y5OyEQvF2=	NF6y[FZUSU6JRWK=
UACC-257	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfDVXdKSzVyPUG2MlEzODFizszN	NWHhXo1xW0GQR1XS
U-87-MG	NYHvT\|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDxUHUzUUN3ME2xOk4{PTJ\|IN88US=>	MX;TRW5ITVJ?
HCC1806	NGnPbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XXTWlEPTB;MU[uO\|A4OSEQvF2=	NEH4PHVUSU6JRWK=
NCI-H2170	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jZeWlEPTB;MUeuNlQ1QCEQvF2=	MX7TRW5ITVJ?
AGS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLaNHlKSzVyPUG3MlM5ODhizszN	M2HrdHNCVkeHUh?=
MEL-HO	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTtTWM2OD1zNz63OVA{KM7:TR?=	MmTaV2FPT0WU
SW48	NYDKVnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r0SGlEPTB;MUeuO\|cyPiEQvF2=	NEnQ[nlUSU6JRWK=
HuP-T4	NVz2fWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojsTWM2OD1zOD6wNlA3KM7:TR?=	M3HqU3NCVkeHUh?=
NCI-H720	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fhcmlEPTB;MUiuNVQxOiEQvF2=	M3\senNCVkeHUh?=
RCC10RGB	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF6LkG2PVch\|ryP	M3rpSHNCVkeHUh?=
HD-MY-Z	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInmUoZKSzVyPUG4MlIzPTRizszN	NIHFWmZUSU6JRWK=
A427	NUjVPZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTF6LkWwPVQh\|ryP	M3XNbHNCVkeHUh?=
HCC2998	NEOxUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfqTWM2OD1zOD62NFUyKM7:TR?=	NWXTdGs1W0GQR1XS
EPLC-272H	NEDEVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF7LkC0N\|Qh\|ryP	M1yxR3NCVkeHUh?=
C32	M3HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\XN2lEPTB;MUmuNFQ2KM7:TR?=	NHLKNY1USU6JRWK=
UMC-11	M2DMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7Yd4hKSzVyPUG5MlIyOjNizszN	M1rpVnNCVkeHUh?=
CaR-1	NUT5fnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3:4OmlEPTB;MUmuOlgxPCEQvF2=	NUfLc3FpW0GQR1XS
KYSE-410	Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPh[YppUUN3ME2xPU46OTN7IN88US=>	NWXUe5p6W0GQR1XS
HuCCT1	M1e0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7YUJNKSzVyPUKwMlYzQTRizszN	M2LKcnNCVkeHUh?=
LB996-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjSTWM2OD1{MD63NVY5KM7:TR?=	MnLWV2FPT0WU
KYSE-70	M2C4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfISXVjUUN3ME2yNE45ODV7IN88US=>	MoTUV2FPT0WU
CAL-72	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTJyLkmxOUDPxE1?	MoXQV2FPT0WU
Capan-2	M2rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3mO5RKSzVyPUKxMlA1OTNizszN	MnnqV2FPT0WU
PANC-08-13	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXvU3AyUUN3ME2yNU4zPTF3IN88US=>	NEDZeHhUSU6JRWK=
SBC-1	NYXFfoZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTJzLkOwPFEh\|ryP	MUTTRW5ITVJ?
MFM-223	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3WcYNKSzVyPUKxMlM{PDJizszN	MnjkV2FPT0WU
BB49-HNC	NVvzUFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Ts[GlEPTB;MkGuOVcyPiEQvF2=	NIS4e4VUSU6JRWK=
SH-4	M3HUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPXTWM2OD1{MT62OlE5KM7:TR?=	M4Ltc3NCVkeHUh?=
HuO9	NIPkdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3my[WlEPTB;MkGuPVgzPSEQvF2=	MmrWV2FPT0WU
AM-38	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTpTmVKSzVyPUKyMlA1QDVizszN	NVrsNVBXW0GQR1XS
A431	NYm0eIRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG3TWM2OD1{Mz6yNVE6KM7:TR?=	NEPsSnFUSU6JRWK=
YAPC	M1XqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkf3TWM2OD1{Mz6yOlUyKM7:TR?=	NGO3fY9USU6JRWK=
LU-139	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3YNXhlUUN3ME2yN{41QDB7IN88US=>	M1v3TXNCVkeHUh?=
HEC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXpXGhiUUN3ME2yN{41QTN5IN88US=>	MYnTRW5ITVJ?
SCC-25	M1vxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIK2TJVKSzVyPUK0MlMxODZizszN	MmLSV2FPT0WU
HT-29	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTFcYdNUUN3ME2yOE4{QDJ\|IN88US=>	NGnubZlUSU6JRWK=
PC-14	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmn2TWM2OD1{ND62OVcyKM7:TR?=	MY\TRW5ITVJ?
Calu-6	M4fFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfNTWM2OD1{NT61NFcyKM7:TR?=	Mlr0V2FPT0WU
SJRH30	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTJ3Lk[0PVYh\|ryP	Mkn4V2FPT0WU
ChaGo-K-1	NX3FVmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnY[ZJKSzVyPUK2MlE3OjlizszN	Mn3yV2FPT0WU
IA-LM	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTCW3JKSzVyPUK2MlM3PDVizszN	MXzTRW5ITVJ?
GP5d	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[1TWM2OD1{Nj60OFkyKM7:TR?=	M1vXXnNCVkeHUh?=
NCI-H2291	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLTdXZKSzVyPUK2MlY2PDFizszN	NVPK[5hVW0GQR1XS
BALL-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL1TWM2OD1{Nj65N\|k4KM7:TR?=	M4nQXXNCVkeHUh?=
HCC1954	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXOTWM2OD1{Nj65PFA5KM7:TR?=	M{j4[nNCVkeHUh?=
NCI-H2452	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJ5LkSxOlMh\|ryP	M2PMVHNCVkeHUh?=
LU-99A	NFLCd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zFcWlEPTB;MkeuOVU5OiEQvF2=	NUHqNnFIW0GQR1XS
NTERA-S-cl-D1	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXKeYtKSzVyPUK3MlczQTlizszN	NYjVPZNXW0GQR1XS
PANC-10-05	NHPjRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlO0TWM2OD1{Nz63O\|c2KM7:TR?=	MXTTRW5ITVJ?
NCI-H2405	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnhdXc4UUN3ME2yO{46Ozh5IN88US=>	NGX2[oFUSU6JRWK=
MDA-MB-415	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJ6LkSxN\|ch\|ryP	MUnTRW5ITVJ?
NCI-H2342	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTJ6LkWyPFEh\|ryP	M2nKU3NCVkeHUh?=
TGBC24TKB	M1K5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DnU2lEPTB;MkiuO\|EyPyEQvF2=	NXnwRnY4W0GQR1XS
LU-134-A	NXvhXll[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrYNJZKSzVyPUK4MlkzPjFizszN	Ml7qV2FPT0WU
SCC-4	NGLJPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILBVHRKSzVyPUOxMlA1QTRizszN	NYHBd4I5W0GQR1XS
Saos-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTNzLkmzNFYh\|ryP	NYO4fmkyW0GQR1XS
RERF-LC-MS	NXLXbnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN{LkiyN\|Eh\|ryP	Mn72V2FPT0WU
M14	NVn0e2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnEUXZZUUN3ME2zNk46PzZ2IN88US=>	MlrDV2FPT0WU
HPAF-II	M13weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVm5fZJOUUN3ME2zN{42ODFzIN88US=>	M1WxcXNCVkeHUh?=
NCI-H1755	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojITWM2OD1\|ND6zN\|A2KM7:TR?=	MXHTRW5ITVJ?
D-392MG	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkixTWM2OD1\|NT64Olc1KM7:TR?=	NIfvSIJUSU6JRWK=
A704	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUj1[ppbUUN3ME2zOk4xPDJ5IN88US=>	NGjqOGlUSU6JRWK=
CP50-MEL-B	NUjIRpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vBWmlEPTB;M{[uNVkyOSEQvF2=	NGCyZmhUSU6JRWK=
EW-18	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LDR2lEPTB;M{[uOFUzKM7:TR?=	Ml;XV2FPT0WU
WM-115	NFzld5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELHe4JKSzVyPUO2MlgxQTlizszN	NHH0WJRUSU6JRWK=
LU-65	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTN5LkG0NVch\|ryP	M2jqdXNCVkeHUh?=
NCI-H1563	NYHBelJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTN5LkK0PFQh\|ryP	M4nvW3NCVkeHUh?=
DBTRG-05MG	NFe4e5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PhVWlEPTB;M{iuNFY6OSEQvF2=	MWTTRW5ITVJ?
NCI-H630	NF7wXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NID3fHpKSzVyPUO4MlQ4OTRizszN	NF\OOlNUSU6JRWK=
NCI-H1155	NX;zd3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTRTWM2OD1\|OT6yOFIh\|ryP	M4XBV3NCVkeHUh?=
OVACR-3	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXPWYh7UUN3ME2zPU46OTl3IN88US=>	NFjtfGFUSU6JRWK=
OAW-42	M2\5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzWdlJ1UUN3ME20NE41OjV6IN88US=>	NVzpXm5OW0GQR1XS
JVM-2	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2P3fGlEPTB;NEGuNlQyPSEQvF2=	M3XHTHNCVkeHUh?=
C3A	NH23e5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTRzLkO0OFch\|ryP	MV\TRW5ITVJ?
HT55	M3e2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDvOIhKSzVyPUSyMlI5PDFizszN	NX3wOplCW0GQR1XS
OVCAR-4	NYLYOJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvD[HloUUN3ME20Nk4zQTd2IN88US=>	NX;xW3Z6W0GQR1XS
MEG-01	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjoOIhKSzVyPUSyMlQ3OTZizszN	NWDwfXJbW0GQR1XS
NCI-H82	NGfScJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXW4V5FrUUN3ME20N{46QDl{IN88US=>	NXPzbnBUW0GQR1XS
JEG-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWO1[GpjUUN3ME20OE46PDdizszN	MkfjV2FPT0WU
BPH-1	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLrPXJsUUN3ME20Ok4{QTl6IN88US=>	NIO5OpFUSU6JRWK=
MPP-89	NYDqd3FOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTR5LkK4PVgh\|ryP	MVfTRW5ITVJ?
ALL-PO	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LUUGlEPTB;NEeuOFE5QCEQvF2=	NELKWVFUSU6JRWK=
HT	NYHMUGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHtR\|JtUUN3ME20O{41QTJizszN	NIHBSIVUSU6JRWK=
NCI-H2347	NGXKNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rKSmlEPTB;NEiuNFcyPSEQvF2=	M2XVTHNCVkeHUh?=
A2780	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWG1dYptUUN3ME20PU41OjJ6IN88US=>	MULTRW5ITVJ?
KARPAS-299	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR7LkWxNVkh\|ryP	MkfnV2FPT0WU
NCI-H1651	NH7wSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPvTWM2OD12OT64PFIyKM7:TR?=	M1zQdXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	+ Expand Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0) Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

+ Expand

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03870919	Not yet recruiting	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	May 15 2019	Not Applicable
NCT03870919	Not yet recruiting	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	May 15 2019	Not Applicable
NCT03820830	Not yet recruiting	Breast Cancer Recurrent	International Breast Cancer Study Group\|Pfizer	May 1 2019	Phase 3
NCT03820830	Not yet recruiting	Breast Cancer Recurrent	International Breast Cancer Study Group\|Pfizer	May 1 2019	Phase 3
NCT03609047	Not yet recruiting	Breast Cancer Stage II\|Breast Cancer Stage III	European Organisation for Research and Treatment of Cancer - EORTC\|Pfizer	May 7 2019	Phase 2
NCT03609047	Not yet recruiting	Breast Cancer Stage II\|Breast Cancer Stage III	European Organisation for Research and Treatment of Cancer - EORTC\|Pfizer	May 7 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products3

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 25 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products3

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 25 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products3

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)